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http://dx.doi.org/10.1016/j.jmii.2013Background: To determine clinical predictors and impact of Gram-negative nonfermenters
(GNNFs) infections among adults with community-onset bacteremia in the emergency depart-
ment (ED).
Methods: Adults with bacteremia visiting the ED from January 2007 to June 2008 were identi-
fied retrospectively. Demographic characteristics, underlying illnesses, clinical conditions,
bacteremic pathogens, antimicrobial agents, and outcome, were retrieved from chart records.
Results: After the exclusion of 261 patients with contamination of blood cultures and 24 pa-
tients referred from other hospitals, 518 adults with community-onset bacteremia were
eligible; their mean age was 65.1 years, with slight predominance of female (262 patients,
50.6%). Of a total of 565 bacteremic isolates, Escherichia coli (228 isolates, 40.4%) and Kleb-
siella pneumoniae (100, 17.7%) were the major microorganisms. GNNFs caused bacteremia in
31 (6.0%) patients. A higher proportion of inappropriate antibiotic therapy in the ED (87.1% vs.
26.5%, p < 0.001) and higher 28-day crude mortality rate (19.4% vs. 8.4%, p Z 0.05) were
observed in bacteremic patients caused by GNNFs than those not caused by GNNFs. In further
analysis of KaplaneMeier survival curve, patients with GNNF bacteremia had a worse outcome
than those due to other pathogens (pZ 0.04). Multivariate analysis revealed that the indepen-
dent predictors related to GNNF bacteremia included surgery during previous 4 weeks prior tot of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng Li Road, 70403 Tainan,
u.edu.tw (C.-C. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.08.004
Gram-negative nonfermenters bacteremia in the ED 93ED arrival [odds ratio (OR), 10.79; 95% confidence interval (CI), 1.84e63.24; p Z 0.01], resi-
dents in long-term healthcare facilities (OR, 4.62; 95% CI, 2.08e10.29; p < 0.001), and malig-
nancy (OR, 2.24; 95% CI, 1.10e5.40; p Z 0.02).
Conclusion: For adults with bacteremia visiting the ED, GNNF is associated with a higher mortal-
ity rate andmore inappropriate empirical antibiotic therapy in the ED. To allow early administra-
tion of empirical antibiotics, several clinical predictors of GNNF infections were identified.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Bacteremia is a serious life-threatening condition and is
associated with significant healthcare costs and mortality,
with a case-fatality rate as high as 30%.1,2 Bacteremia is
also a common and deadly problem in patients visiting
emergency departments (EDs).3 Early administration of
appropriate empirical antibiotics has been shown repeat-
edly to decrease the mortality in patients with community-
acquired infections.1,4,5
Gram-negative nonfermenters (GNNFs) are classified as
aerobic microorganisms that are incapable of utilizing
carbohydrates as a source of energy or degrade them via an
oxidative rather than fermentative pathway.6 Of GNNFs,
Pseudomonas aeruginosa is the most important pathogen
and other members include diverse genera, such as Acine-
tobacter, Alcaligenes, Burkholderia, Chryseobacterium,
Flavimonas, andWeeksiella.7 These organisms are naturally
in vitro resistant to commonly used antimicrobial agents,
such as penicillin, aminopenicillins, and first or second
generation cephalosporins, and are increasingly important
opportunistic pathogens in immunocompromised hosts.7,8
These infections have been increasingly reported and
result in a high mortality rate among these patients.9e15
Focusing on P. aeruginosa or Acinetobacter baumannii
bacteremia, themost prevalentGNNF inUSAandTaiwan,6,9,15
several investigations also demonstrated that the delay in
initiation of effective treatment would be associated with
adverse outcomes.16e20 Community-acquired bacteremia
caused by these microorganisms had been also reported in
recent years.9,15,19,21,22 It is not surprising that the appro-
priate antibiotics for community-onset GNNF infections are
dissimilar to those for common community-onset pathogens
(i.e., Escherichia coli, Klebsiella pneumoniae, staphylococci,
and streptococci). However, no clinical predictors ofGNNFs in
patients with community-onset bacteremia have been
recognized to assist the ED clinicians. This led us to conduct
this study to compare the clinical characteristics and out-
comes of patients with GNNF bacteremia and those infected
by other pathogens and to determine clinical predictors for
GNNF infections in bacteremic adults who visited the ED.Methods
Study design
This retrospective study was conducted at a teaching hos-
pital of approximately 1000 beds in southern Taiwan, andthere were approximately 65,000 annual visits to the ED
during the study period. The local institutional review
board approved this study.
Study setting and protocol
The records of adult patients (age 18 years) who visited the
ED between January 2007 and June 2008 with a positive blood
culture were included. Patients with contaminated blood
cultures or the identificationof bacteremiaprior to visiting the
ED and those transferred from other hospitals were excluded.
The medical records of adults visiting the ED with
bacteremia were reviewed. Clinical characteristics, vital
signs, Pittsburgh bacteremia severity scores, comorbidities,
initial syndrome, and laboratory data, were collected after
each patient’s visit to the ED. At that time, the duration
and type of antimicrobial agent administration in the ED,
microbiological results, source of bacteremia, further hos-
pitalization, and length of stay were derived from the chart
records. Moreover, recent events during the 4 weeks prior
to ED arrival, including hospitalizations, prior antimicrobial
use, invasive procedures, and/or surgery performed, were
also recorded as a previous report.23 Multiple bacteremic
episodes in a single patient were considered to be distinct
episodes, if separated by at least 7 days or if there were
different causes for the ED visits.
The primary outcome was the 28-day mortality after ED
arrival. If patients were discharged within 28 days after ED
arrival andwere not followed-up at our hospital, the required
information was retrieved by telephone interview. The pa-
tients who could not be reached by telephonewere excluded.
Microbiologic studies
Nurses collected two sets of blood cultures from different
peripheral veins or arteries within 30 minutes. Each set of
blood cultures routinely consisted of one bottle for aerobic
culture and another for anaerobic culture, with 5e8 mL of
blood/bottle. The culture bottles were immediately trans-
ported to the clinicalmicrobiology laboratory, loaded into the
BACTEC 9240 system (Becton Dickinson and Company,
Franklin Lakes, NJ, USA), and incubated for 5 days or until the
system indicated bacterial growth. Culture bottles that had
bacterial growth were Gram-stained, and the contents of the
bottles were subcultured onto plates with blood agar (Tryp-
ticase soy agar II 5% sheep blood; Becton Dickinson), Levine
eosinemethylene blue agar (Becton Dickinson and Company),
chocolate agar, and Centers for Disease Control and Preven-
tion (CDC) anaerobic blood agar (Becton Dickinson and
94 C.-W. Chiu et al.Company) for further identification. Biochemical tests and
automatic identification systems were used for final identifi-
cation. In vitro antimicrobial susceptibility of blood isolates
were studied by the KirbyeBauer method on MuellereHinton
agar, andwas interpreted according to theClinical Laboratory
Standard Institute guidelines.24
Definitions
Polymicrobial bacteremia was defined as the isolation of
more than one microbial species from each bacteremic
episode. A polymicrobial culture with a mixture of GNNF
and non-GNNF pathogen was regard as a GNNF episode.
Community-onset bacteremia indicates that the place of
onset of the bacteremic episode is the community,
including long-term healthcare facility (LTHCF)-acquired
and community-acquired bacteremia, as previously
described.25 Therefore, patients transferred from the
hospital-associated LTHCF or other hospitals were not
enrolled in our populations. Appropriate antimicrobial
therapy was defined as the use of a drug to which the iso-
lated pathogen was in vitro susceptible, and inappropriate
antimicrobial therapy as a drug to which the isolated
pathogen was in vitro nonsusceptible or no administration
of any antibiotic in the ED. If, for a patient, there was
administration of more than one drug of the same class, we
counted the drug used longer as the prescribed antibiotic.
The severity of bloodstream infection at the time of onset
would be measured by the Pittsburgh bacteremia score, a
validated scoring system based on vital signs, mental sta-
tus, mechanical ventilation, and the presence of cardiac
arrest.26 Malignancy refers to hematological malignancies
or solid tumors. The definitions of comorbidities were as
previously described.27 The growth of coagulase-negative
staphylococci, Propionibacterium acnes, Micrococcus,Figure 1. Flowchart of patient enrollment. GNNF Z Gram-negaBacillus, or Peptostreptococcus in the blood culture bottle,
will be regarded as contaminated, according to the previ-
ously described criteria.28 The sources of bacteremia were
regarded to be low respiratory tract infections, urinary
tract infections, wound infections, skin and soft-tissue in-
fections, intra-abdominal infections, or primary blood-
stream infections according to the definitions of the CDC.29
Data analysis
Statistical analyses were performed using SPSS for Win-
dows, Version 15.0 (SPSS, Chicago, IL, USA). Continuous
variables are expressed as mean  standard deviations and
were compared by the Student t test. Categorical variables,
expressed as numbers and percentages, are compared by
the Chi-square test or Fisher exact test. KaplaneMeier
survival curves was performed for the different duration of
survival after the onset of bacteremia between patient due
to GNNF and those to non-GNNF. All variables with p < 0.1
in the univariate analysis are contributory by means of a
Cox regression model with a backward deletion algorithm
to develop the risk factors of 28-day mortality and clinical
predictors of GNNF infections. A p value < 0.05 is consid-
ered statistically significant.
Results
Demographics and clinical characteristics of adults
with bacteremia
During the 18-month study period, there were blood culture
samples from 19,308 patients. Therewere 518 (2.6%) eligible
adults visiting the ED with clinically significant bacteremia
(i.e., true bacteremia), as shown in Fig. 1. Most (403, 77.8%)tive nonfermenters; LTHCF Z long-term healthcare facilities.
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and 37 (7.1%) were transferred from the EDs of the other
hospitals. Their mean age was 65.1 years, and 262 (50.6%)
were females. Major comorbidities were cardiovascular
diseases (259 patients, 50.6%), diabetes mellitus (190 pa-
tients, 36.7%), malignancy (112 patients, 21.6%), chronic
renal insufficiency (85 patients, 16.4%), liver cirrhosis (69
patients, 13.3%), old stroke (34 patients, 6.6%), and chronic
pulmonary diseases (24 patients, 4.6%), as shown in Table 1.
In our population, 365 patients (70.5%)were subsequently
admitted to general wards, and 68 patients (13.1%) to the
intensive care units (ICU), whereas 10 patients (1.9%) were
transferred to other hospitals. Fourteen patients had recent
invasive procedures within 4 weeks prior to ED arrival, and
endoscope was the major procedure (9 patients, 1.7%), fol-
lowed by bronchoscopy (4 patients, 0.8%), and cystoscopy
(1 patient, 0.2%), whereas eight patients had recent surgery,
mainly abdominal operation (4 patients, 0.8%). Fourteen
patients died in the ED and 37 patients died after admission.
None died after discharge from the ED or after being trans-
ferred to other hospitals. Therefore, the 28-day mortality
rate was 9.1% (47 patients) and the crude mortality 9.8% (51
patients).Table 1 Clinical characteristics, comorbidities, initial syndrome
negative nonfermenters (GNNF) bacteremia in the emergency de
Clinical variables GNNF bacteremia, pa
(%)
Yes, n Z 31
Old age,  65 y 16 (51.6)
Female 11 (35.5)
Recent events within the past 4 weeks
Hospitalization 11 (35.5)
Invasive procedures 3 (9.7)
Surgery 3 (9.7)
Residents in LTHCF 14 (45.2)
Initial presentation in the ED
Sepsis 21 (67.7)
Febrile neutropenia 2 (6.5)
Comorbidities
Cardiovascular diseases 17 (54.8)
Diabetes mellitus 7 (22.6)
Malignancy 13 (41.9)
Chronic renal insufficiency 5 (16.1)
Liver cirrhosis 1 (3.2)
Old stroke 0 (0)
Chronic pulmonary diseases 0 (0)
Laboratory abnormalities in the EDb
Leukocytes > 9  109/L 16/30 (53.3)
Platelets < 100  109/L 3/29 (10.3)
Blood urea nitrogen > 20 mg/dL 17/29 (58.6)
Serum creatinine > 1.5 mg/dL 11/29 (37.9)
C-reactive protein > 100 mg/L 9/29 (31.0)
Glucose > 200 mg/dL 7/25 (28.0)
Serum albumin < 3.5 g/dL 4/10 (40.0)
a Comparison of variables between bacteremic adults infected by G
b Not all patients had the indicated laboratory data.
ED Z emergency department; LTHCF Z long-term healthcare facilitiClinical predictors of GNNF bacteremia
To determinate clinical predictors of GNNF bacteremia in the
ED, the univariate analysis compared the ED variables of pa-
tientswithGNNF bacteremia and those infected by pathogens
other thanGNNFs.The concernedvariables includedpatients’
characteristics, events prior to the ED, initial presentations,
the place of disease onset, comorbidities, and laboratory
parameters, as shown in Table 1. Patients with a recent sur-
gical (9.7% vs. 1.0%,pZ 0.009) or invasive procedure (9.7% vs.
2.3%, pZ 0.04), recent hospitalizationwithin the past 4week
(35.5% vs. 15.6%,pZ0.004),underlyingmalignancy (41.9%vs.
20.3%, p Z 0.005), or residents in LTHCF (45.2% vs. 13.1%,
p < 0.001), were more likely to have GNNFs bacteremia.
However, patients with leukocytosis (>9.0  109 cells/L;
53.5% vs. 65.3%; pZ 0.009) or hypoalbuminemia (<3.5 g/dL;
40.0% vs. 65.9%, p Z 0.006) were less likely to have GNNF
infections. In a multivariate analysis of these data (Table 1),
three factors independently associated with GNNF bacter-
emia were recent surgery [odds ratio (OR) 10.79; 95%
confidence interval (CI), 1.84e63.24; pZ 0.006], residents in
LTHCF (OR, 4.62; 95% CI, 2.08e10.29; p < 0.001), and un-
derlying malignancy (OR, 2.24; 95% CI, 1.10e5.40; pZ 0.02)., and laboratory parameters of adults with or without Gram-
partment
tient number Total patient number
(%), n Z 518
pa
No, n Z 487
272 (55.9) 288 (55.6) 0.64
251 (51.5) 262 (50.6) 0.08
76 (15.6) 87 (16.8) 0.004
11 (2.3) 14 (2.7) 0.04
5 (1.0) 8 (1.5) 0.009
64 (13.1) 78 (15.1) <0.001
311 (63.9) 332 (62.2) 0.66
5 (1.0) 7 (1.4) 0.06
242 (49.7) 259 (50.0) 0.57
183 (37.6) 190 (36.7) 0.09
99 (20.3) 112 (21.6) 0.005
80 (16.4) 85 (16.4) >0.99
68 (14.0) 69 (13.3) 0.10
34 (6.9) 34 (6.6) 0.25
24 (4.9) 24 (4.6) 0.38
314/481 (65.3) 330/511 (64.5) 0.009
85/476 (17.9) 88/505 (17.4) 0.30
265/474 (55.9) 282/503 (56.1) 0.77
143/478 (30.0) 154/507 (30.4) 0.36
167/443 (37.7) 176/472 (37.3) 0.47
129/421 (30.6) 136/446 (30.5) 0.78
85/129 (65.9) 89/139 (64.0) 0.006
NNF and those by other pathogens in univariate analysis.
es.
96 C.-W. Chiu et al.Microbiological analysis
Table 2 reveals the total of 565 isolates in 518 patients with
true bacteremia, with a predominance of Gram-negative
aerobes (406 isolates, 71.9%). The family Enter-
obacteriaceae (364 isolates, 64.4%) played a major role;
and E. coli (228, 40.4%) and Klebsiella species (100, 17.6%)
were the major pathogens. The isolates with extended-
spectrum b-lactamase producers accounting for 5.2% (12
isolates) and 9.0% (9 isolates) respectively were discovered
in E. coli and Klebsiella species. Staphylococci (68 isolates,
12.0%) and Streptococci (69, 12.2%) were the major
Gram-positive aerobes, and methicillin-resistant S. aureus
account for 42.6% of S. aureus. Only seven anaerobes
(Clostridium species, 4 isolates; 3 Bacteroides species)
were discovered in our population. Of note, the distribution
of bacteremic isolates in the monomicrobial and poly-
microbial episode was similar.
Of 31 GNNF isolates, P. aeruginosa (16 isolates, 51.6%)
was the most common pathogen, followed by Acineto-
bacter species (6 isolates, 19.4%), Burkholderia pseudo-
mallei (3 isolates, 9.7%), Burkholderia cepacia (2 isolates,Table 2 The distribution of 565 isolates in 513 patients with co
Bacteremic isolates
Total, n Z 565
Gram-negative aerobes 406 (71.9)
Enterobacteriaceae 364 (64.4)
Escherichia coli 228 (40.4)
Klebsiella species 100 (17.7)
Enterobacter cloacae 14 (2.5)
Proteus species 12 (2.1)
Salmonella enteritidis 3 (0.5)
Citrobacter species 3 (0.5)
Serratia marcescens 2 (0.4)
Morganella morganii 2 (0.4)
Glucose nonfermenters 31 (5.5)
Pseudomonas aeruginosa 16 (2.8)
Acinetobacter species 6 (1.1)
Burkholderia pseudomallei 3 (0.5)
Burkholderia cepacia 2 (0.4)
Chryseobacterium species 2 (0.4)
Flavimonas oryzihabitans 1 (0.2)
Weeksella virosa 1 (0.2)
Vibrio vulnificus 4 (0.7)
Aeromonas 4 (0.7)
Haemophilus influenzae 2 (0.4)
Moraxella catarrhalis 1 (0.2)
Gram-positive aerobes 152 (26.9)
Staphylococci 68 (12.0)
Methicillin-resistant S. aureus 29 (5.1)
Streptococci 69 (12.2)
Streptococcus viridans 15 (2.6)
Streptococcus pneumoniae 10 (1.8)
Streptococcus bovis 8 (1.4)
Enterococci 15 (2.6)
Anaerobes 7 (1.2)
Bacteroides species 4 (0.7)
Clostridium species 3 (0.5)6.5%) Chryseobacterium species (2 isolates, 6.5%), Flavi-
monas oryzihabitans (1 isolates, 3.2%), and Weeksella
virosa (1 isolates, 3.2%). Notably, of 31 episodes of GNNF
bacteremia, 14 (45.2%) were noted in patients from LTHCF
and seven (22.5%) were polymicrobial infections. In in vitro
susceptibility analysis of 31 GNNF bacteremic isolates, >
90% were susceptible to cefepime (96.7%), imipenem
(93.5%), ceftazidime (90.3%), or piperacillin/tazobactam
(90.3%). Fewer isolates were susceptible to ciprofloxacin
(80.6%), amikacin (83.8%), or piperacillin (87.1%).
Clinical outcome and antibiotic therapy of GNNF
bacteremia
The association of severity in the ED, subsequent hospitali-
zation, length of hospital stay, source of bacteremia, antibi-
otic therapy in the ED, and clinical outcome was assessed in
the univariate analysis (Table 3). More polymicrobial in-
fections (22.6% vs. 7.8%, pZ 0.01), vascular catheter-related
bloodstream infections (16.1% vs. 8.2%, pZ 0.003), intensive
careunit (ICU) admissions (29.0% vs. 12.1%,pZ 0.01), and the
receipt of inappropriate antimicrobial therapy in the EDmmunity-onset bacteremia
Number of bacteremic isolates (%)
Monomicrobial, n Z 450 Polymicrobial, n Z 115
325 (72.2) 81 (70.4)
293 (65.1) 71 (61.7)
186 (41.3) 42 (36.5)
78 (17.3) 22 (19.1)
10 (2.2) 4 (3.5)
9 (2.0) 3 (2.6)
3 (0.6) 0 (0)
3 (0.6) 0 (0)
2 (0.4) 0 (0)
2 (0.4) 0 (0)
24 (5.3) 7 (6.1)
11 (2.4) 5 (4.3)
4 (0.8) 2 (1.7)
3 (0.6) 0 (0)
2 (0.4) 0 (0)
2 (0.4) 0 (0)
1 (0.2) 0 (0)
1 (0.2) 0 (0)
4 (0.8) 0 (0)
2 (0.4) 2 (1.7)
1 (0.2) 1 (0.9)
1 (0.2) 0 (0)
120 (26.6) 32 (27.8)
57 (12.6) 11 (9.6)
25 (5.5) 4 (3.5)
52 (11.6) 17 (14.8)
11 (2.4) 4 (3.5)
8 (1.8) 2 (1.7)
6 (1.3) 2 (1.7)
11 (2.4) 4 (3.5)
4 (0.8) 3 (2.6)
2 (0.4) 2 (1.7)
2 (0.4) 1 (0.9)
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GNNF bacteremia than those without GNNF bacteremia. Of
note, there was a trend in a higher 28-day mortality rate in
patients with GNNF infections (19.4% vs. 8.4%, pZ 0.05), and
in the survival analysis, the difference of 28-day survival rate
between two groups was significant (pZ 0.04; Fig. 2).
In further analysis of crude mortality in patients with
bacteremia due to species within GNNFs, the highest was
P. aeruginosa (5/16, 31.3%), followed by Acinetobacter spe-
cies (1/6, 16.7%). No fetal episode was discovered in patients
with bacteremia due to B. pseudomallei, B. cepacia, Chrys-
eobacterium species, F. oryzihabitans, andW. virosa.Risk factors of mortality in bacteremic patients
The association of clinical variables, laboratory parame-
ters, the source and severity of bacteremia, appropriate
antibiotic treatment, and 28-day mortality rates inTable 3 Clinical variables and outcome among adults visiting the
to Gram-negative nonfermenters. Data are expressed as numbers
Characters
Yes
Polymicrobial bloodstream infections 7 (2
Pittsburgh bacteremia score  4 points 6 (2
Source of bacteremia
Urinary tract 7 (2
Lower respiratory tract 6 (1
Biliary tract 5 (1
Vascular catheter 5 (1
Skin and soft-tissue 3 (9
Primary bacteremia 3 (9
Bone and joint 1 (3
Intra-abdomen 0 (0
Liver abscess 0 (0
Infective endocarditis 0 (0
Antibiotic therapy in the ED
Time to administration (hours), mean  SD 0.8
Inappropriate empirical therapy 27
Type of antibiotics
Cephalosporins, 1st generation 13
Cephalosporins, 2nd generation 5 (1
Cephalosporins, 3rd generation 4 (1
Cephalosporins, 4th generation 2 (6
Aminopenicillins/b-lactamase inhibitors 2 (6
Ureidopenicillins/b-lactamase inhibitors 2 (6
Ureidopenicillins 2 (6
Fluoroquinolones 1 (3
Glycopeptides 0 (0
Penicillin G 0 (0
Combination with an aminoglycoside 1 (3
No antibiotic 0 (0
Clinical outcome
Hospitalization through the ED 26
ICU Admission through the ED 9 (2
28-day crude mortality 6 (1
ICU Z intensive care unit; SD Z standard deviation.bacteremic patients are shown in Table 4. The following
were significantly associated with 28-day mortality: old age
( 65 years; 70.2% vs. 54.1%; p Z 0.03); male (70.2% vs.
47.3%; p Z 0.003); residents in LTHCF (36.2% vs. 12.9%;
p < 0.001); GNNF (12.8% vs. 5.3%; p Z 0.04); high Pitts-
burgh bacteremic score ( 4 points; 68.1% vs. 13.6%,
p < 0.001); admitted to ICU through the ED (25.5% vs.
11.7%, p Z 0.007); initial presentation with sepsis (83.0%
vs. 62.2%, pZ 0.005) or febrile neutropenia (6.4% vs. 0.8%,
pZ 0.01); comorbidities with malignancy (42.6% vs. 19.5%,
p Z 0.001); high serum creatinine (> 1.5 mg/dL; 52.1% vs.
28.1%, p Z 0.001); high serum blood urea nitrogen
(>20 mg/dL; 81.3% vs. 53.4%; p < 0.001); and high
C-reactive protein (>100 mg/L; 53.5% vs. 34.9%; pZ 0.02).
However, in multivariate analyses, only four factors
independently associated with 28-day mortality were high
Pittsburgh bacteremic score ( 4 points; OR, 11.11; 95% CI,
5.38e22.92; p < 0.001), underlying malignancy (OR, 4.49;
95% CI, 2.05e9.84; p < 0.001), residents in LTHCF (OR,emergency department (ED) with or without bacteremia due
(percentage), unless indicated specifically
Gram-negative nonfermenter
bacteremia, patient number (%)
p
, n Z 31 No, n Z 487
2.6) 38 (7.8) 0.01
2.6) 90 (18.5) 0.90
2.6) 175 (35.9) 0.13
9.4) 54 (11.1) 0.15
6.1) 40 (8.2) 0.17
6.1) 13 (2.7) 0.003
.7) 41 (8.4) 0.74
.7) 82 (16.8) 0.29
.2) 6 (1.2) 0.35
) 22 (4.5) 0.63
) 27 (5.5) 0.39
) 22 (4.5) 0.63
7  2.59 0.94  3.97 0.92
(87.1) 129 (26.5) <0.001
(41.9) 171 (35.1) 0.59
6.1) 56 (11.5) 0.57
2.9) 103 (21.1) 0.21
.5) 16 (3.3) 0.31
.5) 82 (16.8) 0.10
.5) 6 (1.2) 0.08
.5) 8 (1.6) 0.12
.2) 12 (2.5) 0.57
) 5 (1.0) >0.99
) 2 (0.4) >0.99
.2) 17 (3.5) >0.99
) 26 (5.3) 0.93
(83.9) 407 (83.6) >0.99
9.0) 59 (12.1) 0.01
9.4) 41 (8.4) 0.05
Figure 2. KaplaneMeier survival curves showing the differ-
ence between patients with or without bacteremia due to
Gram-negative nonfermenters (p Z 0.04).
98 C.-W. Chiu et al.2.61; 95% CI, 1.21e5.61; pZ 0.01), and bacteremia due to
urinary tract infections (OR, 0.16; 95% CI, 0.12e0.49;
p Z 0.001).
Risk factors of mortality in patients with GNNF
bacteremia
The association of clinical variables, laboratory parameters,
the source and severity of bacteremia, appropriate antibi-
otic treatment, and 28-day mortality rates in GNNF bacter-
emic patients were examined by univariate analysis. The
following were significantly associated with 28-day mortal-
ity: malignancy (6/13, 46.2% vs. 0/18, 0%; pZ 0.002); high
Pittsburgh bacteremic score ( 4 points; 4/6, 66.7% vs. 2/25,
8.0%, p Z 0.006); initial presentation with febrile neu-
tropenia (2/6, 33.3% vs. 0/25, 0%, pZ 0.03); thrombocyto-
penia (<150  109/L; 4/6, 66.7% vs. 3/23, 13.0%, pZ 0.01);
and high serum blood urea nitrogen (> 20 mg/dL; 6/6, 100%
vs. 11/25, 44.0%; p Z 0.02). However, in multivariate ana-
lyses, a risk factor independently associated with 28-day
mortality was not discovered.
Discussion
In the present study, a high proportion of inappropriate
empirical therapy and a worse outcome in patients with
bacteremia due to GNNF was discovered in the ED. There-
fore, clinical variables noted in the present study, espe-
cially the presence of recent surgery (i.e., during 4 weeks
prior to ED arrival), would be useful for ED clinicians to
identify the population at risk for GNNF bacteremia and
choose appropriate antimicrobial agents.
Previous studies have repeatedly demonstrated that the
administration of appropriate empirical antibiotics will
improve the clinical outcome in patients with community-
acquired or nosocomial bloodstream infections.1,4,5 To our
knowledge, there was no clinical study dealing with theassociation between appropriate antibiotics and the outcome
of individuals with GNNF bacteremia in the English literature.
However, with regard to Pseudomonas and Acinetobacter
bacteremia, several reports have demonstrated that a delay
in the use of effective antimicrobial agents would be associ-
atedwith a highermortality.17,18,20 In the present study, these
two pathogens also account for a major proportion of GNNF
infections, and the relationship of a high mortality rate and
GNNFbacteremiawas observed in our population.Thus, itwas
important to identify clinical predictors of GNNF bacteremia
to facilitate early administration of appropriate therapy.
Similar to previous investigation focusing on patients with
bacteremia due to individual bacterium within GNNF (espe-
cially on P. aeruginosa),8,23 the poor outcome in patients
with GNNF bacteremia was discovered in the analysis of
KaplaneMeier curve in the present study. However, no study
grouping all GNNFs together was discovered to analyze the
mortality in the past. Although, in a multivariate analysis,
the GNNF was not an independent risk factor of 28-days
mortality, which was similar to a previous opinion that un-
derlying host factors was strongly associated with the
outcome for each of these organisms.8 Our suspicion is that it
may beexplained by the smaller patient number due toGNNF
bacteremia than due to other causativemicroorganisms (31/
518, 6.0% vs. 487/518, 94.0%; p < 0.001) in our population.
GNNFs are known to be major causes of healthcare-
associated infections, particularly in patients who were
hospitalized and critically ill,8 and Pseudomonas and Acine-
tobacter species were the prevalent pathogens among noso-
comial GNNF infections in the USA and Taiwan.6,9,15 However,
community-acquired infections due to GNNFs have been
increasingly reported in recent years.9,15,19,21,22 Similar to
these reports, 54.8% of GNNF bacteremic episodes were
regarded as acquired in the community in our population,
because ED clinicians mainly manage patients from the com-
munity (440/518, 84.9%) and LTHCFs (78/518, 15.1%). GNNF
infections were often prevalent in hospitalized patients; the
present study only indicated the population after exclusion of
hospitalized patients in other hospitals, to assist the ED cli-
nicians to administer the appropriate antibiotics early.
Of GNNF bacteremia in the ED, there were three (9.7%)
episodes of community-acquired B. pseudomallei infection.
To our knowledge, B. pseudomallei infection is often re-
ported from northern Australia and Southeast Asia,30,31 Until
recently Taiwan could be regarded as an endemic area of
melioidosis, because thereweremany indigenous cases from
southern Taiwan reported to the CDC, Taiwan, after floods or
typhoons.29 So it is not surprising that these cases of
melioidosis can be found in our population. Our clinical data
may be the representative overview of community-onset
bacteremia in southern Taiwan and helpful for local ED cli-
nicians in the choice of appropriate antimicrobial agents.
In this ED-based study emphasizing clinical predictors of
GNNF bacteremia in the ED, the most powerful predictor
was recent surgery. It was consistent with a study of P.
aeruginosa infection.32 It was not surprising that P. aeru-
ginosa was a leading pathogen in our population. In addition
to a strong association of GNNF infection and healthcare
facilities in a previous demonstration,7,8 another indepen-
dent predictor associated with GNNF bacteremia (i.e.,
malignancy) had been also discovered in previous studies
with a majority of nosocomial-acquired P. aeruginosa
Table 4 Univariate analysis of risk factors for 28-day mortality in all bacteremic adults visiting the emergency department
Variables Patient number (%) p
Nonsurvivor, n Z 47 Survivor, n Z 471
Old age,  65 y 33 (70.2) 255 (54.1) 0.03
Male 33 (70.2) 223 (47.3) 0.003
Residents in LTHCF 17 (36.2) 61 (12.9) <0.001
Inappropriate antibiotics in the ED 20 (42.6) 136 (28.9) 0.05
Bacteremic isolates
Polymicrobial 4 (8.5) 41 (8.7) >0.99
Enterobacteriaceaea 26 (55.3) 321 (68.1) 0.07
Gram-positive coccia 18 (38.2) 131 (27.8) 0.13
Gram-negative nonfermentersa 6 (12.8) 25 (5.3) 0.04
Severity-of-illness markers in the ED
Pittsburgh bacteremia score  4 points 32 (68.1) 64 (13.6) <0.001
Admitted to intensive care units 12 (25.5) 55 (11.7) 0.007
Initial syndrome in the ED
Sepsis 39 (83.0) 293 (62.2) 0.005
Febrile neutropenia 3 (6.4) 4 (0.8) 0.01
Major comorbidities
Cardiovascular diseases 26 (55.3) 233 (49.5) 0.44
Malignancy 20 (42.6) 92 (19.5) 0.001
Diabetes mellitus 18 (38.3) 172 (36.5) 0.80
Chronic renal insufficiency 10 (21.3) 75 (15.9) 0.34
Liver cirrhosis 7 (14.9) 62 (13.2) 0.73
Major source of bacteremia
Low respiratory tract 15 (31.9) 45 (9.6) <0.001
Primary bacteremia 12 (25.5) 73 (15.5) 0.07
Urinary tract 4 (8.5) 178 (37.8) 0.001
Skin and soft-tissue 4 (8.5) 40 (8.5) >0.99
Biliary tract infections 2 (4.3) 43 (9.1) 0.41
Laboratory examination in the EDb
Leukocyte > 9  109/L 25/47 (53.2) 305/464 (65.7) 0.08
Platelet < 100  109/L 13/47 (27.7) 75/458 (16.4) 0.05
Blood urea nitrogen > 20 mg/dL 39/48 (81.3) 243/455 (53.4) <0.001
Serum creatinine > 1.5 mg/dL 25/48 (52.1) 129/459 (28.1) 0.001
C-reactive protein > 100 mg/L 23/43 (53.5) 153/439 (34.9) 0.02
Glucose > 200 mg/dL 11/45 (24.4) 125/401 (31.2) 0.35
a All included monomicrobial and polymicrobial bacteremic isolates.
b Not all patients had the indicated laboratory data.
ED Z emergency department; LTHCF Z long-term healthcare facilities.
Gram-negative nonfermenters bacteremia in the ED 99bacteremia.17,22 Although the investigation discussing the
risk factors of Acinetobacter species infection was not re-
ported in the English literature, we suspect that these
predictors were reasonably demonstrated because the P.
aeruginosa was a major pathogen in our population.
In general, it was important to identify clinical predictors
of GNNF bacteremia to facilitate early administration of
appropriate therapy. When ED clinicians face patients with a
high risk of GNNF bacteremia, the in vitro susceptibility an-
alyses in the current study also offer them to choose cefta-
zidime, cefepime, imipenem, or piperacillin/tazobactam as
empirical therapy. Even for patients with a history of b-lac-
tam allergy, ciprofloxacin with or without gentamicin com-
binationmay be an alternative therapy. This susceptibility in
the present study was similar to that in a previous investi-
gation focusing on community-acquired P. aeruginosa
bacteremia,21 and higher than that in previous reports on
hospital-acquired P. aeruginosa bacteremia.16,17There are several limitations inherent to the design of
this study. First, although we included all patients with
bacteremia in the ED for an 18-month period, the study was
conducted in the ED of a single tertiary hospital in Taiwan.
Our findings may not be generalizable to other populations.
Second, the outcome data of two groups must be cautiously
interpreted, given the differences in their characteristics.
However, the multivariate analyses should minimize this
limitation. Third, the data of recent antimicrobial exposure
prior to ED visits were unavailable based on the study
design, it may be an important risk factor of GNNF in-
fections. Finally, the small size of the GNNF bacteremia
group may have limited the detection of other risk factors.
In conclusion focusing on adults with bacteremia in the
ED, the impact of GNNF infections on appropriateness of
empirical antimicrobial therapy and mortality rate was
found in our population. Three clinical predictors of GNNF
infections, including recent surgery, residences in LTHCFs,
100 C.-W. Chiu et al.and the presence of underlying malignancy, were identified.
Based on these findings, clinicians are able to identify the
patients with GNNF infections at an early stage, allowing
timely administration of appropriate drugs, such as cefe-
pime, imipenem, ceftazidime, or piperacillin/tazobactam.Conflicts of interest
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